This week, we will discuss post-trial follow-up for EMPA-Kidney. What are the longer-term effects of empagliflozin for patients with chronic kidney disease?
The Ondansetron Ballet: Torsades de Pointes
Re”FINE”ing the role of non steroidal MRAs in Cardio Kidney Metabolic syndrome
Playing It Safe: Can Felzartamab Fill the Gap in AMR Treatment?
The pressure is on! Unravelling the ESPRIT of Intensive vs Standard BP Control
This week, we will discuss the ongoing saga of blood pressure targets in patients with hypertension. This time its ESPRIT (Effects of Intensive Systolic Blood Pressure Lowering Treatment in Reducing Risk of Vascular Events) making a case for case for intensive BP control in most hypertensive individuals, including those with a history of diabetes and stroke.